ÑÎËáÈ¥ÑõÉöÉÏÏÙËØ,phenylephrine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÅµçƵÂÊ,discharge frequencyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
èÛéÚËáÅçÍÐάÁÖ,pentoxyverine citrateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÎËᾫ°±Ëá,arginine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò½Ò©Êг¡,pharmaceutical marketÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ADR,Alternative Dispute ResolutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ê¡¼¶,provincial levelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°¢ÄªÎ÷ÁÖÄÆ,Amoxicillin sodiumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
̼Ëáïç,lanthanum carbonateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ºÉÒÆÂçºÏÎï,Charge-Transfer ComplexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÎËáÂé»ÆËØ,ephedrine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸´·½°±·ÓÍ鰷Ƭ,compound paracetamol and amantadine hydrochloride tabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÎËáÆÕ³¿¨Òò×¢ÉäÒº,procaine hydrochloride injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»îÐÔ´úлÎï,active metaboliteÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢ÉúÎï¼ì¶¨·¨,microbiological assayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ó«¹âÆ«ÕñÃâÒß·ÖÎö,Fluorescence polarization immunoassayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
øÓÕµ¼,enzyme inductionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±½»·àäåï§,bencycloquidium bromideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûËɳÚËØD,Cytochalasin DÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ºÒ©½ð¶î,Consumption sumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹²¡¶¾µ°°×,Antiviral proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¤Ã¸ÒÖÖÆ¼Á,Kinase inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²¹Ì弤»î,complement activationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ùÒòÒ©Îï,gene drugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò©Æ·¹ÜÀí·¨,Drug Administration LawÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ÝÊ»ÄÜÁ¦,driving abilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ã׸ñÁÐÄθÆ,Mitiglinide calciumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐÂÔØÌå,new carrierÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µÈ¸ßÏßͼ,Contour MapÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐÂÀǶ¾ËØB,neochamaejasmine BÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò°´ó¶¹,Glycine sojaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
רÀû¼ìË÷,patent retrievalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ñ×֢ʹ,inflammatory painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ÌС°ô×´¸Ë¾ú,Corynebacterium parvumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Õû¸Ä´ëÊ©,rectification measuresÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò»Ëõ¶þÒÒ¶þ´¼,diethylene glycolÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Darzens·´Ó¦,Darzens reactionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶þ´Îг²¨·¢Éú,Second harmonic generationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶¾ÐÔÔ¤²â,toxicity predictionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒÒ»ùÊïºì,ethyl eosinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÎËáÃÀ½ð¸Õ°·,memantine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ¨ËáÄÆ,Sodium cholateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶¯Á¦Ñ§Ñо¿,kinetics studyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒõµÀ˨,Vaginal suppositoryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒÒÏ©»ùÒÒÃÑ,ethyl vinyl etherÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µç·ÖÎö·½·¨,electrochemical determinationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³¦ÈÜÆ¬,Enteric-coated tabletÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ʽðÖÜת,capital turnoverÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ÙÈýÔªÏàͼ,pseudo-ternary phase diagramsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°¸Àýʽ½Ìѧ,case teachingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×¢ÉäÓðÂɳÀû²¬,oxaliplatin for injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Í»ÊÍ,initial burst releaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ë®½â¶¯Á¦Ñ§²ð·Ö,hydrolytic kinetic resolutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
άÉúËØEÑÌËáõ¥,vitamin E nicotinateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½á¹¹È·Ö¤,Structural IdentificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÎËáÍ·æßËûÃÀõ¥,cefetamet pivoxil hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»¯Ñ§ºÏ³É·¨,chemical synthesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
C18Öù,C18 columnÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏúÊÛÁ¿,sales volumeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁòÇèËáºìÃ¹ËØ,erythromycin thiocyanateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Àë×Ó½»»»É«Æ×·¨,ion exchange chromatographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ß·Ö×ÓÔÓÖÊ,High molecular weight impuritiesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò©·¿ÍйÜ,Pharmacy TrusteeshipÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áöϸ°ûÖê,Tumor cell linesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÓÃÒ©×Éѯ,medication consultationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
K_(ATP)ͨµÀ,K_(ATP) channelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸´·½»Ç°·¼×‡fßòƬ,Compound Sulfamethoxazole TabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ÙÒ©,counterfeit drugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·¨Âɹ涨,Legal regulationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éñ¾°±ËáøÒÖÖÆ¼Á,neuraminidase inhibitorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò©Æ··çÏÕ¹ÜÀí,drug risk managementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÎËá¶þÑõ±ûàº,dioxopromethazine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÎËáÒÀƥ˹͡,Epinastine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Çŵ±´ÌØËá,Fenofibric acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹À£ÑñÒ©,antiulcer drugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶þ½×µ¼Êý¹âÆ×·¨,Second order derivative spectrophotometryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶îҶǰƤÖÊ,prefrontal cortexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×¢ÉäÓÃÀ¼Ë÷Àßò,lansoprazole for injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂýÐÔÉö¶¾ÐÔ,Chronic nephrotoxicityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹ÒҸβ¡¶¾»îÐÔ,Anti-HBV activityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ȱѪƤ°ê,ischemic skin flapÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ßÇßò·¨,carbazole methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö©Öë¶¾ËØ,Spider venomÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×é֯Ũ¶È,Tissue concentrationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³õÔÈËÙ·¨,Initial average rate methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×é°·H1Þ׿¹¼Á,Histamine H1 antagonistsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹²¡¶¾»úÖÆ,Antiviral mechanismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼±ÐÔÓ¦¼¤,acute stressÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÊÖÐÔת»¯,chiral inversionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò©ÎïתÔ˵°°×,drug transporterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ú¼ÒÒ©ÎïÕþ²ß,national drug policyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÎËáÂÈÃ×ÅÁÃ÷,clomipramine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´«Í³ÊµÑé,traditional experimentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ó²¼þÉ豸,hardware equipmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Ö¼¶ÓÅ»¯,hierarchy optimizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹úÃñÒâʶ,national consciousnessÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·çÏÕ¼à²â,risk monitoringÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±±ÃÀÖÞ,North AmericaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±¡Ä¤·ÖÉ¢·¨,Film dispersion methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò©Æ··çÏÕ,drug riskÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|